Biovaxys Financial Statements From 2010 to 2024
| BVAXF Stock | USD 0.04 0 5.24% |
Check Biovaxys Technology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biovaxys Technology's main balance sheet or income statement drivers, such as , as well as many indicators such as . Biovaxys financial statements analysis is a perfect complement when working with Biovaxys Technology Valuation or Volatility modules.
Biovaxys |
Biovaxys Technology Corp OTC Stock Shares Outstanding Analysis
Biovaxys Technology's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Biovaxys Technology Shares Outstanding | 106.72 M |
Most of Biovaxys Technology's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biovaxys Technology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Biovaxys Technology Corp has 106.72 M of shares currently outstending. This is 40.89% lower than that of the Healthcare sector and about the same as Biotechnology (which currently averages 106.85 M) industry. The shares outstanding for all United States stocks is 81.34% higher than that of the company.
Biovaxys Technology Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biovaxys Technology's current stock value. Our valuation model uses many indicators to compare Biovaxys Technology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biovaxys Technology competition to find correlations between indicators driving Biovaxys Technology's intrinsic value. More Info.Biovaxys Technology Corp is rated below average in return on equity category among its peers. It is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biovaxys Technology's earnings, one of the primary drivers of an investment's value.About Biovaxys Technology Financial Statements
Biovaxys Technology stakeholders use historical fundamental indicators, such as Biovaxys Technology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biovaxys Technology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biovaxys Technology's assets and liabilities are reflected in the revenues and expenses on Biovaxys Technology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biovaxys Technology Corp. Please read more on our technical analysis and fundamental analysis pages.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320 and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. BIOVAXYS TECHNOLOGY is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Biovaxys OTC Stock
Biovaxys Technology financial ratios help investors to determine whether Biovaxys OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biovaxys with respect to the benefits of owning Biovaxys Technology security.